TEL AVIV, Israel, June 29, 2010 /PRNewswire-FirstCall/ -- BSP, which develops and commercializes advanced products for the non invasive, accurate diagnosis of heart diseases, announced today that its Add-On product, the HyperQ AD-100 (http://www.bsp.co.il/pdf/HyperQ AD-100 Pic.pdf), intended for improved diagnostic performance of Stress ECG, has been granted the European CE conformance mark. The HyperQ AD-100 product is an add-on system with the HyperQ technology which is incorporated in parallel to existing standard stress ECG systems. The integration of the HyperQ AD-100 into Stress ECG systems enables accurate and sensitive diagnosis of Ischemic Heart Disease, a leading cause of death in the world.
The unique technology developed by BSP is implemented in a non invasive manner and does not involve exposure to radiation or other hazards to patients. It is highly effective in diagnosing sick people and in ruling out disease in healthy individuals. The HyperQ AD-100 enables physicians to benefit from the clinical advantages of the technology without the need to replace their existing installed Stress ECG system.
BSP CEO, Nissim Greisas: "The integration of the HyperQ Add-On systems into the vast installed base of standard Stress ECG systems significantly expands our potential global market. The worldwide annual stress ECG system market is estimated at $200M, and the total standard ECG installed base represents an estimated $800M market for the new product."
CE mark was also granted to BSP's software product - the HyperQ-AN. This product enables analysis with the unique HyperQ technology and can be employed in OEM and licensing business models in existing commercial stress ECG systems, such as the company's collaboration with Schiller AG.
Founded in 2000, BSP is dedicated to providing novel, risk free and highly reliable solutions for the diagnosis and monitoring of cardiovascular disease. BSP's proprietary HyperQ(TM) technology is implemented in cardiac systems that offer accurate, low-cost and risk free cardiac monitoring and allows, for the first time, an effective diagnosis of ischemic heart disease in broad populations. BSP is a traded company on the Tel Aviv Stock Exchange since 2006 (TASE:BSP). The company's international offices are located in Tel Aviv, Israel and Rockville, Maryland, USA.
For more information please contact: Nissim Greisas, CEO, Biological Signal Processing Ltd. firstname.lastname@example.org Tel. +972-3-6474840
SOURCE BSP - Biological Signal Processing Ltd